Company intelligence / Profile preview
x-nuclear diagnostics
Columbus, Ohio, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
X-Nuclear Diagnostics is a biotechnology company focused on developing targeted radiopharmaceuticals for cancer imaging and therapy. The company specializes in ligands targeting the Gastrin-Releasing Peptide Receptor (GRPR), which is highly expressed in prostate, breast, and pancreatic cancers. Their theranostic approach combines diagnostic imaging to identify patients with therapeutic radionuclide delivery to treat the disease. X-Nuclear's technology aims to improve the precision of oncology treatments through molecularly targeted nuclear medicine.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalPeptideBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on x-nuclear diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on x-nuclear diagnostics.